TRACON Pharmaceuticals, Inc. (TCON)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -6.89 Million USD | 75.27% |
| 2022 | -27.89 Million USD | 1.6% |
| 2021 | -28.34 Million USD | -74.73% |
| 2020 | -16.22 Million USD | 27.24% |
| 2019 | -22.29 Million USD | 35.82% |
| 2018 | -34.74 Million USD | -90.77% |
| 2017 | -18.21 Million USD | 29.9% |
| 2016 | -25.97 Million USD | -10.69% |
| 2015 | -23.46 Million USD | -279.79% |
| 2014 | -6.17 Million USD | 18.27% |
| 2013 | -7.56 Million USD | -44.66% |
| 2012 | -5.22 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -3.21 Million USD | -889.19% |
| 2024 Q2 | -2.91 Million USD | 9.34% |
| 2023 Q1 | -7.31 Million USD | -25.39% |
| 2023 Q4 | 407 Thousand USD | 125.63% |
| 2023 FY | -6.89 Million USD | 75.27% |
| 2023 Q3 | -1.58 Million USD | -103.85% |
| 2023 Q2 | -779 Thousand USD | 89.35% |
| 2022 FY | -27.89 Million USD | 1.6% |
| 2022 Q4 | -5.83 Million USD | 8.55% |
| 2022 Q3 | -6.37 Million USD | -2.21% |
| 2022 Q2 | -6.23 Million USD | 33.95% |
| 2022 Q1 | -9.44 Million USD | -23.27% |
| 2021 Q2 | -8.84 Million USD | -78.57% |
| 2021 Q4 | -7.66 Million USD | -11.36% |
| 2021 Q1 | -4.95 Million USD | -18.63% |
| 2021 Q3 | -6.88 Million USD | 22.23% |
| 2021 FY | -28.34 Million USD | -74.73% |
| 2020 Q4 | -4.17 Million USD | -8.55% |
| 2020 Q1 | -3.88 Million USD | -1.89% |
| 2020 Q2 | -4.31 Million USD | -11.07% |
| 2020 Q3 | -3.84 Million USD | 10.8% |
| 2020 FY | -16.22 Million USD | 27.24% |
| 2019 FY | -22.29 Million USD | 35.82% |
| 2019 Q4 | -3.81 Million USD | 24.98% |
| 2019 Q2 | -6.24 Million USD | 12.89% |
| 2019 Q3 | -5.08 Million USD | 18.57% |
| 2019 Q1 | -7.16 Million USD | 7.35% |
| 2018 Q1 | -8.18 Million USD | -28.88% |
| 2018 Q4 | -7.73 Million USD | 14.88% |
| 2018 FY | -34.74 Million USD | -90.77% |
| 2018 Q3 | -9.08 Million USD | 6.72% |
| 2018 Q2 | -9.73 Million USD | -18.9% |
| 2017 Q3 | 1.39 Million USD | 122.02% |
| 2017 Q1 | -6.92 Million USD | -13.91% |
| 2017 Q2 | -6.33 Million USD | 8.53% |
| 2017 FY | -18.21 Million USD | 29.9% |
| 2017 Q4 | -6.35 Million USD | -555.81% |
| 2016 Q1 | -6.29 Million USD | 41.92% |
| 2016 FY | -25.97 Million USD | -10.69% |
| 2016 Q4 | -6.07 Million USD | -8.54% |
| 2016 Q3 | -5.59 Million USD | 30.12% |
| 2016 Q2 | -8.01 Million USD | -27.26% |
| 2015 Q2 | -2.68 Million USD | 27.69% |
| 2015 Q1 | -3.71 Million USD | -64.76% |
| 2015 FY | -23.46 Million USD | -279.79% |
| 2015 Q4 | -10.83 Million USD | -73.79% |
| 2015 Q3 | -6.23 Million USD | -132.3% |
| 2014 Q1 | -1.33 Million USD | 37.99% |
| 2014 Q2 | -891 Thousand USD | 33.11% |
| 2014 Q3 | -1.7 Million USD | -91.13% |
| 2014 Q4 | -2.25 Million USD | -32.3% |
| 2014 FY | -6.17 Million USD | 18.27% |
| 2013 Q1 | -1.46 Million USD | 0.0% |
| 2013 Q3 | -2.54 Million USD | -81.4% |
| 2013 FY | -7.56 Million USD | -44.66% |
| 2013 Q2 | -1.4 Million USD | 4.17% |
| 2013 Q4 | -2.14 Million USD | 15.6% |
| 2012 FY | -5.22 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -1300.2% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | 27.527% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 77.001% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 89.726% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 56.46% |
| Better Therapeutics, Inc. | -38.26 Million USD | 81.972% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 83.605% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 42.373% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 79.618% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 79.959% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 93.64% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -242.451% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 79.713% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 85.308% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -404.466% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 65.405% |
| Molecular Templates, Inc. | -10.46 Million USD | 34.091% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | 50.907% |
| NexImmune, Inc. | -29.19 Million USD | 76.371% |
| Orgenesis Inc. | -53.63 Million USD | 87.139% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 86.552% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -8741.663% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 57.275% |
| Scopus BioPharma Inc. | -11.71 Million USD | 41.118% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 98.632% |
| Statera Biopharma, Inc. | -98.34 Million USD | 92.986% |
| Trevena, Inc. | -35.28 Million USD | 80.452% |
| Vaxxinity, Inc. | -58.28 Million USD | 88.165% |
| Vaccinex, Inc. | -22.88 Million USD | 69.858% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -558.849% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 86.393% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 5.026% |